Kairos Pharma (KAPA) executive compensation, 2026 proxy

John S. Yu, Chief Executive Officer and Chairman of the Board, was paid $362,915 in 2025, up 323% from $85,741 the year before.

Filed
May 22, 2026
Annual meeting
June 29, 2026
Pay year
2025
Named executives
4
CEO total pay
$362,915+323% vs prior year
CEO pay in equity
21%$75,415 in awards
CEO 2025 bonus
$87,500
CEO 2025 stock awards
$75,415
CFO 2025 stock awards
$142,250
CEO base salary rate
$200,0002025 rate
October 2025 CEO RSUs
190,840Annual vesting
CFO change-control RSUs
250,000Immediate vesting

How Yu was paid

$362,915 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary55%Bonus24%Stock awards21%

Named executive officers

ExecutiveTotal
John S. YuChief Executive Officer and Chairman of the Board$362,915
Neil BhowmickChief Scientific Officer$225,415
Ramachandran MuraliVice President of Research and Development$190,415
Doug SamuelsonChief Financial Officer$254,750

What changed and why

  • $363K$362,915 was CEO total compensation in 2025 versus $85,741 in 2024, including $75,415 in stock awards and an $87,500 bonus.
  • $200K$200,000 was the CEO’s 2025 base salary rate, increased from the $175,000 2024 rate.
  • $106K$106,250, $87,500, and $62,500 were the 2025 base salary rates for the other named executives.
  • Annual cash or stock bonuses are determined by the compensation committee or board and are not formulaically specified.
  • 190,840 RSUs were granted to John Yu in October 2025 and vest on the grant-date anniversary.
  • 250,000 RSUs are specified for the CFO upon a change of control, including prior RSUs and vesting immediately.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.